Advanced Solid Tumors
Conditions
Brief summary
This is a safety, pharmacokinetic and pharmacodynamic study designed to estimate the maximum tolerated dose (MTD), and determine the Recommended Phase 2 Dose (RP2D) of SYHA1801, a BRD4 inhibitor in patients with advanced solid tumors.
Detailed description
This study will be performed in two parts. Part 1 will enroll patients with advanced solid tumors. Patients will receive SYHA1801 orally on Days 1 and 4-31 in the first cycle. Enrollment will follow a dose-escalation schedule until grade 3 drug-related adverse events are observed, at this point the i3+3 enrollment design will be used. Dose increments will be guided by data generated from previous levels. The dose and possibly the schedule will be adjusted to determine the Maximum Tolerated Dose (MTD). If a patient wishes to continuously receive study treatment on completion of Cycle 1, the patient can continue study treatment in 28-day Cycle 2 and subsequent cycles. Part 2 will enroll patients with specific solid tumor which might potentially respond to BRD4 inhibitor. Patients will receive SYHA1801 at a dose and schedule established in Part 1.
Interventions
DRUGDrug: SYHA1801
Drug: SYHA1801 administered orally
Sponsors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Parallel Assignment
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Age ≥18, ≤75 years, no gender limitation. 2. Histologically or cytologically confirmed diagnosis of advanced or metastatic solid tumors, for which standard therapy either does not exist or has proven ineffective, intolerable or inacceptable for the patient. 3. At least one measurable lesion as per RECIST version 1.1. 4. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤1. 5. Life expectancy ≥3 months. 6. Adequate bone marrow reserve, renal and liver function. 7. Women of childbearing potential should agree to use contraceptive measures (such as IUD, contraceptive or condom) during the study and within 6 months after the end of the study; the serum pregnancy test should be negative within 7 days before enrollment, and must be non-lactating subjects; men should agree to use contraceptive measures during the study and within 6 months after the end of the study. 8. Signed informed consent form.
Exclusion criteria
1. Administration of chemotherapy, radiotherapy, biotherapy, endocrine therapy, targeted therapy, immunotherapy and other anti-tumor treatment within 4 weeks before the first dose of the study drug, except the following: using nitrosourea and mitomycin C within 6 weeks, using fluorouracil and small molecule targeted drugs within 2 weeks (or within 5 half time period), using traditional Chinese medicine with anti-tumor indications within 2 weeks. 2. Administration of other unlisted clinical research drugs within 4 weeks before the first dose of SYHA1801. 3. Major organ surgery (excluding biopsy) or significant trauma within 4 weeks before the first dose of SYHA1801. 4. Administration of glucocorticoids or other immunosuppressants within 14 days prior to the first dose of SYHA1801, except the following: local, ocular, intraarticular, intranasal and inhaled glucocorticoids; short-term use of glucocorticoids for preventive treatment. 5. Concomitant therapy with strong CYP3A4 inhibitors or inducers within 14 days. 6. Prior treatment with BET inhibitors. 7. Persistent grade \>1 clinically significant toxicity related to prior antineoplastic therapies (except alopecia). 8. Central nervous system metastasis or meningeal metastasis with clinical symptoms, or other evidence that the patient's central nervous system metastasis or meningeal metastasis has not been controlled, that is not suitable for the group according to the judgment of the investigator. 9. Uncontrollable active infection. 10. History of autoimmune diseases, immunodeficiency, including HIV positive, or other acquired, congenital immunodeficiency, or organ transplant history. 11. Active hepatitis B; positive for hepatitis C antibody. 12. History of serious cardiovascular disease. 13. Inability to swallow oral medications or presence of a gastrointestinal disorder deemed to jeopardize intestinal absorption of SYHA1801. 14. Other serious illness or medical conditions. 15. Alcohol or drug dependence. 16. A clear history of neurological or psychiatric disorders. 17. Pregnant or breast-feeding female. 18. In the opinion of the investigator, not suitable for enrollment due to other reasons.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To evaluate the MTD of SYHA1801 | through study completion, an average of 1 year | The maximum tolerable dose (MTD) (if it has), recommended phase II dose (RP2D) and dosage regimen of SYHA1801. |
| To evaluate AE,SAE and DLT of SYHA1801. | 28 days | The occurrence and frequency of AE, SAE and DLT. To evaluate the safety and tolerability of SYHA1801. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| AUC0-∞ of SYHA1801. | 31 days | To evaluate AUC0-∞ of SYHA1801. |
| Cmax of SYHA1801. | 31 days | To evaluate Cmax of SYHA1801. |
| Tmax of SYHA1801. | 31 days | To evaluate Tmax of SYHA1801. |
| t½ of SYHA1801. | 31 days | To evaluate t½ of SYHA1801. |
| ORR of SYHA1801 | 2 months | To evaluate ORR of SYHA1801 |
| PFS of SYHA1801 | 2 months | To evaluate PFS of SYHA1801 |
| DCR of SYHA1801 | 2 months | To evaluate DCR of SYHA1801 |
| DOR of SYHA1801 | 2 months | To evaluate DOR of SYHA1801 |
| CL/F of SYHA1801. | 31 days | To evaluate CL/F of SYHA1801. |
| AUC0-last of SYHA1801. | 31 days | To evaluate AUC0-last of SYHA1801. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Biomarkers and Beneficiaries | 2 months | To evaluate potential pharmacodynamic biomarkers（C-MYC、MYCN、BCL-2、HEXIM1、CCR2、CD180、VEGFA） and to assess potential beneficiaries（such as hematoma tumors and myelofibrosis） |
Countries
China
Outcome results
None listed